ArticleWorld journal of microbiology & biotechnology2025
Superficial incisional surgical site infections experimentally induced by Staphylococcus aureus in mice: the effect of Bdellovibrio bacteriovorus containing dressing.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bdellovibrio bacteriovorus is an agent that stands out with its predatory properties and has recently been used against pathogens that are frequently resistant to antibiotics. The study was conducted experimentally to determine the effect of dressing application containing Bdellovibrio bacteriovorus on superficial incisional surgical site infection caused by Staphylococcus aureus in mice. In the study, mice were divided into 6 different groups, BB: B. bacteriovorus; NC: Negative Control; PC: Positive Control Methicillin Resistant S. aureus; MRSA + BB: Methicillin Resistant S. aureus + B. bacteriovorus dressing; MRSA + V: Methicillin Resistant S. aureus + Vancomycin; MRSA + BB + V: Methicillin Resistant S. aureus + B. bacteriovorus dressing + Vancomycin group. The treatment procedures were applied over a period of 3 days. Infection symptoms were monitored and recorded at the 24th, 48th, and 72nd hours. In the Staphylococcus aureus + Vancomycin group, all mice developed edema, redness, and fever at 24 h. At 48 h, all mice exhibited edema and redness, with 50% showing fever. At 72 h, 70% of the mice showed edema and redness, and 10% showed fever. In the Staphylococcus aureus + Bdellovibrio bacteriovorus + Vancomycin combined treatment group, all mice exhibited edema, redness, and fever at 24 h. At 48 h, only 20% of the mice showed redness. At 72 h, no edema, redness, fever, purulent discharge, or suture dehiscence was observed. Sepsis developed in 2 of 10 mice in the Staphylococcus aureus + Bdellovibrio bacteriovorus + Vancomycin group. The most effective treatment was in the Staphylococcus aureus + Bdellovibrio bacteriovorus + Vancomycin group. It was determined that sepsis findings were the least in the Staphylococcus aureus + Bdellovibrio bacteriovorus + Vancomycin group. B. bacteriovorus holds the potential to be an effective control agent in preventing or slowing resistance development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.